Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 1981-1996
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1981
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1981
Tumor type | Exosomes source | Cell lines | Function | Mechanism | Ref. |
Gastric cancer | hUCMSCs | HGC-27; MGC-803; SGC-7901 | Conferring tumor chemoresistance | (1) Upregulating the expression of multi-drug resistance-associated genes and proteins; (2) Activating calcium/calmodulin-dependent protein kinases (CaMKs) and Raf/MEK/ERK pathway; and (3) Enhancing the functionality of P-gp/MDR | [13] |
hBMSCs | Animal model | Promoting tumor development | (1) Activating ERK1/2 and p38 MAPK pathways; and (2) Enhancing the expression of VEGF | [55] | |
hBMSCs | SGC-7901 | No effect | NA | [55] | |
hUCMSCs | HGC-27 | Promoting tumor development | (1) Activating the Akt signal pathway; (2) Inducing the epithelial-mesenchymal transition (EMT); and (3) Enhancing the tumorigenicity and stemness | [61] | |
hBMSCs | SGC-7901 | Promoting tumor development | Secreting miR-221 to activate Hedgehog signaling pathway | [64] | |
GC-MSCs | HGC-27 | Promoting tumor development | Increasing the expression of miR-214, miR-221, and miR-222 | [66] | |
mBMSCs | MFC | Promoting tumor development | Delivering UBR2 to activate Wnt/β-catenin signaling pathway | [69] | |
Liver cancer | hBMSCs | HepG-2 | Inhibiting tumor development | (1) Blocking the cell cycle progression; and (2) Inducing tumor cells apoptosis | [93] |
AMSCs | HepG-2 | Inhibiting tumor development and increasing tumor chemosensitivity | Secreting miR-122 to improve chemosensitivity of HepG2 HCC cells and inhibiting tumor development | [83] | |
AMSCs | Huh-7; SMMC-7721 | Increasing tumor chemosensitivity | Delivering miR-199a-3p to improve liver cancer cell line chemosensitivity | [87] | |
mBMSCs | Animal model | Inhibiting tumor development | (1) Promoting tumor cells apoptosis; and (2) Inhibiting angiogenetic activity, metastasis, and invasiveness | [96] | |
AMSCs | Animal model | Inhibiting tumor development | Upregulating local and systemic NK cells | [95] | |
AMSCs | Huh-7; SMMC-7721 | Increasing tumor chemosensitivity | Delivering miR-199a-3p to tumor sites | [87] | |
Pancreatic cancer | hBMSCs | BxPC-3; PANC-1 | Inhibiting tumor development | Secreting miR-1231 to suppress tumor development | [107] |
hBMSCs | PANC-1 | Inhibiting tumor development and promoting tumor cells apoptosis | Downregulating the expression of a disintegrin and a metalloproteinase-9 (ADAM9) | [108] | |
mBMSCs | AsPC-1; PANC-1 | Inhibiting tumor development and promoting tumor cells apoptosis | Delivering miR-124 to regulate the expression of EZH2 | [109] | |
mBMSCs | CFPAC-1 | Inhibiting tumor development | Delivering anticancer agents | [47] | |
Normal fibroblast-like MSCs | PANC-1 | Inhibiting tumor development | Delivering short interfering RNA or short hairpin RNA to target oncogenic KRAS | [105] | |
BMSCs | MiaPaca-2 | Inhibiting tumor development | Loading PTX and gemcitabine monophosphate (GEMP) to pancreatic cancer | [100] | |
BMSCs | Tumor model | Enhancing tumor immunotherapy | Constructing a dual delivery biosystem to achieve the combined therapy | [106] | |
Colorectal cancer | hBMSCs | SW-480 | Promoting tumor development | Activating ERK1/2, p38, and JNK pathways | [55] |
BMSCs | Caco-2; SW-480; SW-620; LoVo; HT-29 | Inhibiting tumor development and promoting tumor cells apoptosis | Upregulating the expression of miR-16-5p to downregulate integrin α2 (ITGA2) | [124] | |
BMSCs | DLD-1; HCT-116; SW-480 | Inhibiting tumor development | Secreting miR-4461 to downregulate the expression of COPB2 | [125] | |
BMSCs | SW-1116; Caco-2 | Inhibiting tumor development and promoting CSCs phenotype | Secreting miR-142-3p to decrease the expression of Numb. (1) Increasing the expression of Notch target genes; and (2) Secreting miR-142-3p to target CD133 and Lgr5 | [126][127] | |
hUCMSCs | HT-29; DLD-1 | Inhibiting tumor development | (1) Downregulating the expression of Integrin alpha6 (ITGA6); and (2) Inhibiting the activity of transforming growth factor-beta1 (TGF-β1) signaling pathway | [128] | |
mBMSCs | C-26; MCF-7 | Inhibiting tumor development | Loading doxorubicin (DOX) to tumor cells | [132] |
- Citation: Zhao LX, Zhang K, Shen BB, Li JN. Mesenchymal stem cell-derived exosomes for gastrointestinal cancer. World J Gastrointest Oncol 2021; 13(12): 1981-1996
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/1981.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.1981